Mucins 5AC (MUC5AC) and 5B (MUC5B) are the major mucins providing the organizing framework for the airway’s mucus gel. We retrieved bronchial mucosal biopsies and bronchial wash (BW) samples through bronchoscopy from patients with chronic obstructive pulmonary disease (n = 38), healthy never-smokers (n = 40), and smokers with normal lung function (n = 40). The expression of MUC5AC and MUC5B was assessed immunohistochemically. The mucin concentrations in BW were determined using the slot-blot technique. The immunohistochemical expression of MUC5AC and MUC5B was localized to goblet cells and submucosal glands. Smokers had higher MUC5AC and lower MUC5B goblet cell expression and higher concentrations of soluble MUC5AC in BW than never-smokers. The MUC5B expression in goblet cells correlated positively with expiratory air flows, diffusing capacity, and the dyspnoea score. Chronic bronchitis, emphysema, and the progression of chronic airflow limitation during a median follow-up time of 8.4 years were associated with higher MUC5AC and lower MUC5B expression in goblet cells. Sustainers, slow progressors, and rapid progressors of airflow obstruction differed in their MUC5B expression at baseline. Emphysema and bronchial wall thickening on CT at a follow-up visit were associated with lower MUC5B expression at baseline. Our findings strengthen the hypothesis that MUC5AC and MUC5B are yet another contributing factor to smoking-associated lung disease progression.
Rationale: Smoking-related chronic obstructive pulmonary disease (COPD) is associated with dysregulated production of mucus. Mucins (MUC) are important both for mucus secretion and epithelial defense. We have examined the distribution of MUC1 and MUC4 in the airway epithelial cells of never-smokers and smokers with and without COPD. Methods: Mucosal biopsies and bronchial wash samples were obtained by bronchoscopy from age- and sex-matched COPD-patients (n = 38; GOLD I-II/A-B), healthy never-smokers (n = 40) and current smokers with normal lung function (n = 40) from the Karolinska COSMIC cohort (NCT02627872). Cell-specific expressions of MUC1, MUC4 and regulating factors, i.e., epithelial growth factor receptor (EGFR) 1 and 2, were analyzed by immunohistochemistry. Soluble MUC1 was measured by quantitative immunodetection on slot blot. Results: The levels of cell-bound MUC1 expression in basal cells and in soluble MUC1 in bronchial wash were increased in smokers, regardless of airway obstruction. Patients with chronic bronchitis had higher MUC1 expression. The expression of MUC4 in cells with goblet cell phenotype was increased in smokers. The expression of EGFR2, but not that of EGFR1, was higher in never-smokers than in smokers. Conclusions: Smoking history and the presence of chronic bronchitis, regardless of airway obstruction, affect both cellular and soluble MUC1 in human airways. Therefore, MUC1 may be a novel marker for smoking- associated airway disease.
Background: The weight regain after successful weight loss is a common challenge. This study aimed to assess the long-term effectiveness of a web-based health behaviour change support system (HBCSS) utilizing persuasive systems design (PSD) and methods of cognitive behavioural therapy (CBT). We have previously demonstrated the two-year effectiveness of the HBCSS. Methods: In total, 532 participants with overweight or obesity (BMI 27–35 kg m−2) were split into three groups with different intensities of intervention: CBT-based group counselling, self-help guidance (SHG), and usual care. These groups were further divided into HBCSS and non-HBCSS groups. The HBCSS was a 52-week programme. The follow-up took five years in total. Results: Mean weight change (%) (95% CI) from baseline among HBCSS and non-HBCSS users was 1.5 (−0.02 to 2.9), p = 0.056 and 1.9 (0.3–3.3), p = 0.005, respectively, at five years. Of the six groups, the SHG group without HBCSS had a statistically significant increase in weight (%) from baseline at five years (3.1, 95% CI 0.6 to 5.6, p = 0.010). The other groups did not have a significant increase in weight. There was no significant difference between groups at five years in weight. Fewer blood pressure medications were started over the five-year period in HBCSS group (p = 0.046). Conclusion: The 12-month HBCSS intervention was not able to maintain reduced weight better than non-HBCSS at 5 years. However, there were significant weight difference favouring HBCSS over the whole 5-year period. The decrease in the need for antihypertensives suggests that the significant weight loss by HBCSS at early years has a health-promoting legacy effect.
21 January 2025 in International Journal of Medical Informatics
Studies have demonstrated that interventions targeting weight loss and body mass index (BMI) reduction can be successful, although the specific factors that influence their effectiveness are still unclear. Behavior change support systems (BCSS) are an approach that aims to help users in their efforts to modify their behavior. A useful tool for assessing BCSS is the Persuasive Systems Design model (PSD), where different features and postulates can be employed. However, it is unknown whether the grouping of software features and design principles, along with behavioral traits, provide a better combination to achieve effective BMI reduction. This study investigates the impact of PSD features, postulates behind the design, and behavioral traits on BMI reduction after six months of utilizing a mobile health behavior change support system (mHBCSS). We examined a subset of 96 individuals from a randomized controlled trial using a mHBCSS for a period of six months. Data was analyzed using Partial Least Squares Structural Equation Modeling (PLS-SEM). We found that 15.3 % in the variance of BMI reduction was explained by the ability of setting goals. Furthermore, users who perceive a system as highly persuasive are more likely to establish goals (R2 = 0.207). Among PSD features, Dialogue Support and Primary Task Support explained 54.9 % of the variance in Perceived Persuasiveness. In addition, both Dialogue Support and Credibility Support have a mutual effect on Primary Task Support (R2 = 0.685). Finally, the system's unobtrusiveness explained 41.1 % of the variance in Dialogue Support. PSD framework and behavior change theories provide significant influence on BMI reduction. Setting a clear and organized objective assists individuals in successfully pursuing their intended results. The findings of this study can help developers and health professionals decide which PSD features and postulates to include to make mHBCSS interventions targeting BMI reduction more effective.
Many mHealth interventions for health behavior change are considered effective for improving health outcomes. However, there is a limited understanding of the role of the components in an intervention on its effectiveness. Insights into intervention components such as content and software features are needed to design efficient and effective interventions. In this study, we conducted an exploratory analysis of objective data from the usage of a weight management app to understand the role of intervention components in weight loss. We identified a positive correlation between weight loss and the use of the intervention. We also found differences in the app feature use among those who lost weight. To lose weight, users needed to comply with the intervention by completing a combination of tasks. They needed to complete 70% of some tasks and up to a maximum of 30% of other tasks. In the future, we hope to use other types of collected data (logged and survey data) to gain more nuanced insights into how interventions are used. With the help of data analytics, we may find optimal paths of use and determine a satisfactory level of compliance to achieve desired goals. This can deepen our understanding of what works in an intervention.
Aberrant mucus secretion is a hallmark of chronic obstructive pulmonary disease (COPD). Expression of the membrane-tethered mucins 3A and 3B (MUC3A, MUC3B) in human lung is largely unknown. In this observational cross-sectional study, we recruited subjects 45–65 years old from the general population of Stockholm, Sweden, during the years 2007–2011. Bronchial mucosal biopsies, bronchial brushings, and bronchoalveolar lavage fluid (BALF) were retrieved from COPD patients (n = 38), healthy never-smokers (n = 40), and smokers with normal lung function (n = 40). Protein expression of MUC3A and MUC3B in bronchial mucosal biopsies was assessed by immunohistochemical staining. In a subgroup of subjects (n = 28), MUC3A and MUC3B mRNAs were quantified in bronchial brushings using microarray. Non-parametric tests were used to perform correlation and group comparison analyses. A value of p < 0.05 was considered statistically significant. MUC3A and MUC3B immunohistochemical expression was localized to ciliated cells. MUC3B was also expressed in basal cells. MUC3A and MUC3B immunohistochemical expression was equal in all study groups but subjects with emphysema had higher MUC3A expression, compared to those without emphysema. Smokers had higher mRNA levels of MUC3A and MUC3B than non-smokers. MUC3A and MUC3B mRNA were higher in male subjects and correlated negatively with expiratory air flows. MUC3B mRNA correlated positively with total cell concentration and macrophage percentage, and negatively with CD4/CD8 T cell ratio in BALF. We concluded that MUC3A and MUC3B in large airways may be a marker of disease or may play a role in the pathophysiology of airway obstruction.